Abstract
Introduction: The aim of the study was to explore whether patients with autosomal dominant polycystic kidney disease (ADPKD) require native nephrectomy prior to kidney transplantation. Methods: A retrospective analysis of 44 ADPKD patients who received deceased donor allogeneic kidney transplantation at Beijing Friendship Hospital (2013–2024) was conducted. Patients were divided into pre-transplantation nephrectomy (PN) group (n = 29) and a non-PN (nPN) group (n = 15). The pre-transplant general status, surgical duration, intraoperative blood loss, postoperative recovery, and survival rates were compared between the two groups. Additionally, total kidney volume (TKV) and adjusted TKV were used to predict ultimate nephrectomy (UN) status via a receiver operating characteristic (ROC) curve analysis. Finally, the nPN group was subdivided to UN group (n = 8) and non-ultimate nephrectomy (nUN) group (n = 7) based on final nephrectomy status, with comparisons made regarding kidney function and survival analysis. Results: The nPN group had better long-term survival (62 vs. 38 months, p < 0.001). ROC analysis showed BSA-TKV had the highest predictive accuracy (sensitivity: 69.44%, specificity: 87.50%). Subgroup analysis indicated post-transplant nephrectomy did not impact long-term survival or kidney function. Conclusion: Pre-transplant nephrectomy in ADPKD patients should be limited to essential cases as it may prolong recovery and reduce survival. Post-transplant nephrectomy is a safer alternative, guided by predictive metrics like BSA-TKV.
Journal Section:
Research Article
References
1.
Colbert
GB
, Elrggal
ME
, Gaur
L
, Lerma
EV
. Update and review of adult polycystic kidney disease
. Dis Mon
. 2020
;66
(5
):1
–14
. 2.
Neumann
HP
, Jilg
C
, Bacher
J
, Nabulsi
Z
, Malinoc
A
, Hummel
B
, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany
. Nephrol Dial Transplant
. 2013
;28
(6
):1472
–87
. 3.
Grantham
JJ
. Clinical practice. Autosomal dominant polycystic kidney disease
. N Engl J Med
. 2008
;359
(14
):1477
–85
. 4.
Saljoghi
R
, Vourch
A
, Renard
B
, Villers
A
, Bouyé
S
. Arterial embolization of polycystic kidneys as an alternative to ergonomic nephrectomy in renal pre-transplantation. Monocentric retrospective study
. Prog Urol
. 2019
;29
(10
):482
–9
. 5.
Uko
CG
. Recognizing and treating autosomal dominant polycystic kidney disease
. Nurse Pract
. 2020
;45
(11
):41
–7
. 6.
Akabane
M
, Nakamura
Y
, Miki
K
, Yokoyama
T
, Ubara
Y
, Ishii
Y
. Effectiveness of nephrectomy and transcatheter arterial embolization before kidney transplantation in autosomal dominant polycystic kidney disease
. Transplant Proc
. 2020
;52
(6
):1680
–3
. 7.
Maxeiner
A
, Bichmann
A
, Oberländer
N
, El-Bandar
N
, Sugünes
N
, Ralla
B
, et al. Native nephrectomy before and after renal transplantation in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
. J Clin Med
. 2019
;8
(10
):1622
. 8.
Jänigen
BM
, Hempel
J
, Holzner
P
, Schneider
J
, Fichtner-Feigl
S
, Thomusch
O
, et al. Simultaneous ipsilateral nephrectomy during kidney transplantation in autosomal dominant polycystic kidney disease: a matched pair analysis of 193 consecutive cases
. Langenbecks Arch Surg
. 2020
;405
(6
):833
–42
. 9.
Kim
J
, Chae
S
, Bae
H
, Kim
JI
, Moon
IS
, Choi
BS
, et al. Clinical outcome of simultaneous native nephrectomy and kidney transplantation in patients with autosomal dominant polycystic kidney disease
. Transplant Proc
. 2016
;48
(3
):840
–3
. 10.
Nunes
P
, Mota
A
, Alves
R
, Figueiredo
A
, Parada
B
, Macário
F
, et al. Simultaneous renal transplantation and native nephrectomy in patients with autosomal-dominant polycystic kidney disease
. Transplant Proc
. 2007
;39
(8
):2483
–5
. 11.
Clavien
PA
, Barkun
J
, de Oliveira
ML
, Vauthey
JN
, Dindo
D
, Schulick
RD
, et al. The clavien-dindo classification of surgical complications: five-year experience
. Ann Surg
. 2009
;250
(2
):187
–96
. 12.
Anselmo
A
, Iaria
G
, Pellicciaro
M
, Sforza
D
, Parente
A
, Campisi
A
, et al. Native nephrectomy in patients with autosomal dominant polycystic kidney disease evaluated for kidney transplantation
. Transplant Proc
. 2019
;51
(9
):2914
–6
. 13.
Abrol
N
, Bentall
A
, Torres
VE
, Prieto
M
. Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: a single-center experience
. Am J Transplant
. 2021
;21
(4
):1513
–24
. 14.
Shumate
AM
, Bahler
CD
, Goggins
WC
, Sharfuddin
AA
, Sundaram
CP
. Native nephrectomy with renal transplantation is associated with a decrease in hypertension medication requirements for autosomal dominant polycystic kidney disease
. J Urol
. 2016
;195
(1
):141
–6
. 15.
Giuliani
A
, Milan Manani
S
, Crepaldi
C
, Domenici
A
, Gastaldon
F
, Corradi
V
, et al. Intraperitoneal pressure in polycystic and non-polycystic kidney disease patients, treated by peritoneal dialysis
. Blood Purif
. 2020
;49
(6
):670
–6
. 16.
Pierre
M
, Moreau
K
, Braconnier
A
, Kanagaratnam
L
, Lessore De Sainte Foy
C
, Sigogne
M
, et al. Unilateral nephrectomy versus renal arterial embolization and technique survival in peritoneal dialysis patients with autosomal dominant polycystic kidney disease
. Nephrol Dial Transplant
. 2020
;35
(2
):320
–7
. 17.
Xu
Y
, Evans
M
, Barany
P
, James
G
, Sjölander
A
, Carrero
JJ
. Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study
. Clin Kidney J
. 2021
;14
(7
):1780
–8
. 18.
Veroux
M
, Zerbo
D
, Basile
G
, Gozzo
C
, Sinagra
N
, Giaquinta
A
, et al. Simultaneous native nephrectomy and kidney transplantation in patients with autosomal dominant polycystic kidney disease
. PLoS One
. 2016
;11
(6
):e0155481
. 19.
Casteleijn
NF
, Geertsema
P
, Koorevaar
IW
, Inkelaar
FDJ
, Jansen
MR
, Lohuis
SJ
, et al. The need for routine native nephrectomy in the workup for kidney transplantation in autosomal dominant polycystic kidney disease patients
. Urol Int
. 2023
;107
(2
):148
–56
. 20.
Reiterová
J
, Tesař
V
. Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment
. Int J Mol Sci
. 2022
;23
(6
):3317
. 21.
Willey
CJ
, Blais
JD
, Hall
AK
, Krasa
HB
, Makin
AJ
, Czerwiec
FS
. Prevalence of autosomal dominant polycystic kidney disease in the European Union
. Nephrol Dial Transplant
. 2017
;32
(8
):1356
–63
. 22.
Burgmaier
K
, Ariceta
G
, Bald
M
, Buescher
AK
, Burgmaier
M
, Erger
F
, et al. Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD)
. Sci Rep
. 2020
;10
(1
):16025
. 23.
Rodríguez-Faba
O
, Breda
A
, Villavicencio
H
. Renal transplantation and polycystic: surgical considerations
. Actas Urol Esp
. 2014
;38
(1
):28
–33
. 24.
Yamamoto
T
, Watarai
Y
, Kobayashi
T
, Matsuda
Y
, Tsujita
M
, Hiramitsu
T
, et al. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation
. Transplantation
. 2012
;93
(8
):794
–8
. 25.
Cristea
O
, Yanko
D
, Felbel
S
, House
A
, Sener
A
, Luke
PPW
. Maximal kidney length predicts need for native nephrectomy in ADPKD patients undergoing renal transplantation
. Can Urol Assoc J
. 2014
;8
(7–8
):278
–82
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
